日本名古屋–(BUSINESS WIRE)–(美国商业资讯)– Menicon Co., Ltd.欣然宣布，其位于马来西亚吉打州的新生产基地已开启商业化生产。该工厂强化了Menicon长期以来在卓越技术、严苛品质及稳定全球隐形眼镜供应方面的承诺。 这家新开业的马来西亚工厂是Menicon迄今为止规模最大的生产基地，专门用于生产日抛隐形眼镜。 全球日抛镜片需求持续攀升，而行业普遍面临供应限制，在此背景之下，Menicon进行了大规模资本投入以扩大产能，尽管新冠疫情带来诸多不确定性，公司仍坚定推进…
Author: Business Wire
Riassunto: Avvio dei processi di produzione commerciale per il più grande impianto di Menicon in Malesia
NAGOYA, Giappone–(BUSINESS WIRE)–Menicon Co., Ltd. è lieta di annunciare l’avvio delle operazioni di produzione commerciale presso il suo nuovo stabilimento di produzione a Kedah, in Malesia. Lo stabilimento ribadisce l’impegno di lunga data di Menic…
Menicons größtes Werk in Malaysia nimmt die kommerzielle Produktion auf
NAGOYA, Japan–(BUSINESS WIRE)–Menicon Co., Ltd. freut sich bekannt zu geben, dass sein neues Produktionswerk in Kedah, Malaysia, die kommerzielle Produktion aufgenommen hat. Das Werk unterstreicht Menicons langjähriges Engagement für technologische E…
Samenvatting: Menicons grootste vestiging in Maleisië start met commerciële productie
NAGOYA, Japan–(BUSINESS WIRE)–Menicon Co., Ltd. maakt met genoegen bekend dat haar nieuwe productiefaciliteit in Kedah, Maleisië, met de commerciële productie is gestart. Deze vestiging versterkt de jarenlange inzet van Menicon ten opzichte van techn…
Menicon’s Largest Malaysia Plant Begins Commercial Production
NAGOYA, Japan–(BUSINESS WIRE)–Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, …
Clinique Announces Visionary Collaboration with ACUVUE to Advance Eye Education in Beauty and Vision
NEW YORK–(BUSINESS WIRE)–Clinique, a globally leading dermatologist guided skincare to makeup brand,* today announces a visionary collaboration in the U.S. with ACUVUE, the world’s leading§ contact lens brand. It unites two global leaders around a po…
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company advancing innovative pharmacologic therapies for refractive eye diseases, today announced key executive promotions designed to strengthen …
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
MISSOULA, Mont.–(BUSINESS WIRE)–OSRX remains licensed and operational in California, continuing uninterrupted access to compounded ophthalmic medications.
Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
TORONTO–(BUSINESS WIRE)– #AlconCanada–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens w…
Alcon lance PRECISION7 au Canada, des lentilles cornéennes révolutionnaires à remplacement hebdomadaire pour commencer chaque semaine avec une nouvelle paire de lentillesMC
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires dédié à aider les gens à voir avec clarté, a annoncé aujourd’hui le lancement au Canada des lentilles sphériques et toriques PRECISION7MD, les seule…
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Boar…
Automata Raises $45M Series C to Build the Operating System for AI-Ready Labs
LONDON–(BUSINESS WIRE)– #aiml–Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ve…
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the su…
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (F…
Resumen: Novaliq recibe la autorización de la FDA para la IND y avanza con NOV05 en un ensayo clínico de Fase II en uveítis anterior no infecciosa
HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, una compañía biofarmacéutica enfocada en el desarrollo de terapias oftálmicas pioneras y de primera categoría, basadas en su exclusiva plataforma de fármacos sin agua EyeSol®, a…
Riassunto: Novaliq ottiene l'autorizzazione IND dalla FDA per far avanzare NOV05 in una sperimentazione clinica di Fase II sull'uveite anteriore non infettiva
HEIDELBERG, Germania e CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, un’azienda biofarmaceutica specializzata in terapie oculari di prima classe e all’avanguardia basate sulla sua esclusiva categoria di farmaci EyeSol® senza acqua, ha annunciato …
Samenvatting: Novaliq ontvangt FDA-goedkeuring voor IND-aanvraag om NOV05 naar een fase II-klinische studie naar niet-infectieuze anterieure uveïtis te brengen
HEIDELBERG, Duitsland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich toelegt op first-in-class en best-in-class oculaire therapieën op basis van zijn unieke watervrije Eyesol®-geneesmiddelencategorie, kondigde vanda…
Novaliq erhält IND-Zulassung der FDA zur Anwendung von NOV05 in einer klinischen Phase-II-Studie zu nicht-infektiöser anteriorer Uveitis
HEIDELBERG, Deutschland und CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, ein Biopharmaunternehmen mit Schwerpunkt auf First- und Best-in-Class-Augentherapeutika, die auf der einzigartigen wasserfreien EyeSol®-Technologie basieren, gab heute beka…
Novaliq obtient l'autorisation de l’IND de la FDA pour faire progresser le NOV05 dans un essai clinique de phase II sur l'uvéite antérieure non infectieuse
HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, une société biopharmaceutique spécialisée dans les traitements oculaires de première classe et les meilleurs de leur catégorie, basés sur sa catégorie unique de médicaments sa…
Novaliq获FDA IND许可推进NOV05用于非感染性前葡萄膜炎的II期临床试验
德国海德堡&美国马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)– Novaliq是一家生物制药公司，专注于基于其独有的无水EyeSol®药物技术体系，开发同类首创及同类最优的眼科治疗方案。公司今日宣布，美国食品药品监督管理局（FDA）已完成对其NOV05研究性新药（IND）申请的审评并予以放行。这是Novaliq首个用于治疗内眼疾病的IND申请。 NOV05是一款基于EyeSol®递送体系的他克莫司眼用溶液，属于创新性的无类固醇外用抗炎治疗方案。本次IND获FDA放行，使公司…